The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
    • Subject Terms:
      Registries*; COVID-19/*prevention & control ; COVID-19 Vaccines/*therapeutic use; Adolescent ; Adult ; Aged ; Aged, 80 and over ; BNT162 Vaccine ; Female ; Humans ; Israel ; Longitudinal Studies ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
    • Abstract:
      Background: The rapid vaccination campaign against COVID-19 in Israel relied on the BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using individual data, to evaluate the effectiveness of the vaccine against new and breakthrough cases.
      Methods: We estimated vaccine effectiveness (VE) for 27 consecutive cohorts, each comprised of individuals vaccinated on specific days. VE against new COVID-19 cases was evaluated for five SARS-CoV-2-related outcomes: infection, symptomatic disease, hospitalisation, severe/critical disease and death. For breakthrough cases, rate reduction was evaluated for hospitalisation, severe/critical disease and death. Outcomes were evaluated at predetermined time-periods after vaccination, the last one dedicated to individuals who became SARS-CoV-2-positive 22-28 days after the second dose.
      Findings: The highest VE estimates against new cases in ≥16 year old individuals, for all outcomes, were reached at the 15-21 day period after the second dose, ranging between 97.7% (95% CI: 95.9-98.7%) for deaths and 98.6% (95% CI: 97.8-99.1%) for severe/critical disease. VE estimates of the 14-20 day period after the first dose ranged between 54.3% (95% CI: 50.6-57.8%) for infection and 77.3% (95% CI: 71.2-82.1%) for severe/critical disease. VE rose more slowly among ≥80 year old individuals. Rate reductions of breakthrough complications were highest at the 22-28 day period after the second dose, ranging between 47.4% (95% CI: 4.3-71.2%) for death and 66.2% (95% CI: 44.2-79.6%) for severe/critical disease.
      Interpretation: The BNT162 vaccine is highly effective in preventing new SARS-CoV-2 cases. Among ≥80 year old individuals, high effectiveness develops more slowly. In breakthrough cases, vaccination reduces complications and death.
      Funding: None.
      Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest
      (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
    • References:
      JAMA. 2021 Jun 22;325(24):2457-2465. (PMID: 33956048)
      N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250)
      Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739)
      J Infect. 2021 Apr;82(4):e8-e10. (PMID: 33472093)
      JAMA. 2021 Sep 21;326(11):1001-1002. (PMID: 34406361)
      Lancet. 2021 May 1;397(10285):1646-1657. (PMID: 33901420)
      N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
      JAMA Netw Open. 2021 Jun 1;4(6):e2115985. (PMID: 34097044)
      BMJ. 2021 May 13;373:n1088. (PMID: 33985964)
      JAMA. 2021 Apr 6;325(13):1261-1262. (PMID: 33571363)
      Lancet. 2021 May 15;397(10287):1819-1829. (PMID: 33964222)
      N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
      Hum Genomics. 2021 Feb 3;15(1):10. (PMID: 33536081)
      Lancet. 2021 Jul 31;398(10298):385-387. (PMID: 34274038)
      MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500. (PMID: 33793460)
      J Infect. 2021 May;82(5):e23-e24. (PMID: 33548358)
      Euro Surveill. 2021 Apr;26(17):. (PMID: 33928898)
      Cell. 2021 May 13;184(10):2587-2594.e7. (PMID: 33861950)
      Clin Infect Dis. 2022 Feb 11;74(3):472-478. (PMID: 33999127)
    • Contributed Indexing:
      Keywords: Breakthrough cases; COVID-19; SARS-CoV-2; Vaccine effectiveness
    • Accession Number:
      0 (COVID-19 Vaccines)
      N38TVC63NU (BNT162 Vaccine)
    • Publication Date:
      Date Created: 20210919 Date Completed: 20211111 Latest Revision: 20240403
    • Publication Date:
      20240403
    • Accession Number:
      PMC8445746
    • Accession Number:
      10.1016/j.ebiom.2021.103574
    • Accession Number:
      34537449